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How does the Merkel Polyomavirus
Lead to a Lethal Cancer? Many
Answers, Many Questions, and a
New Mouse Model
Candice D. Church1 and Paul Nghiem1,2,3,4
The Merkel cell polyomavirus (MCPyV), discovered in 2008, drives the development
of most Merkel cell carcinomas (MCCs) through several canonical mechanisms.
A glaring gap in our knowledge remains the basis by which MCPyV, among all 12
human polyomaviruses, is the only one that causes cancer in humans. Moreover,
initial attempts by numerous groups have failed to reproduce MCC in mice using
oncoproteins from this polyomavirus. Verhaegen et al. report MCPyV small
T-antigen-expressing transgenic mice that now provide insight into in vivo
transformation mechanisms.
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Merkel cell carcinoma is a rare and
aggressive human neuroendocrine skin
cancer, with a disease-associated
mortality of B50% (Lemos et al.,
2010). Although reported incidences
are increasing rapidly, it remains an
orphan disease, with B1600 new
cases per year in the United States.
Accordingly, until recently, little was
known about its pathogenesis and few
clinical trials were available. MCC is
associated with clonal integration of the
Merkel cell polyomavirus in about 80%
of cases (Feng et al., 2008), whereas
a subset of cases appear to be
truly independent of this virus. MCC
typically arises on the UV-exposed skin
of Caucasian individuals, and it often
has a clinically benign appearance that
may resemble a painless nodular cyst.
Figure 1 shows representative clinical
and microscopic features of a Merkel
cell carcinoma.
The development of MCC involves
several molecular steps, including upre-
gulation of cell cycle progression
proteins such as cyclin-E, inactivation
of tumor suppressor proteins such as
retinoblastoma (Rb) (Sihto et al., 2011),
as well as immune evasion (Afanasiev
et al., 2013a; Paulson et al., 2014).
Great insight into the biology of this
cancer has been obtained through
characterization of human tumor mate-
rial, including MCC tumor cell lines.
However, despite extensive effort, no
animal model has been developed to
determine how individual MCPyV
oncoproteins interact with host cell
pathways in vivo.
In this issue of the Journal of Investi-
gative Dermatology, Verhaegen et al.,
demonstrate that expression of MCPyV
small T-antigen (sT-Ag) results in dysre-
gulation in epidermal differentiation in
embryonic mice and in squamous cell
carcinoma in situ when inducibly
expressed in adult mice (Verhaegen
et al., 2015). Furthermore, the authors
demonstrate that the ‘‘LSD’’ (Large
T-antigen Stabilization Domain) of the
sT-Ag is necessary for transformation
by this oncoprotein via the ubiquitin
E3 ligase pathway.
Oncoproteins from the Merkel virus:
what do we know?
A watershed finding regarding the etiol-
ogy of MCC was the discovery in 2008
of the Merkel cell polyomavirus by the
Chang-Moore group (Feng et al., 2008).
They demonstrated that in most MCCs
the viral DNA was clonally integrated
into the host cell DNA, indicating that
each tumor arose from a single cell and
that the virus likely had an important
etiologic role.
We now know that exposure to
MCPyV is nearly ubiquitous, with anti-
bodies specific to the capsid proteins
of this virus often arising early in child-
hood (Chen et al., 2010). In contrast, the
development of MCC is rare and typi-
cally delayed by six to seven decades
following initial virus exposure. Indeed,
the presence of MCPyV does not lead
directly to any apparent human disease,
and this virus is often present on normal
skin. Our current understanding of how
this virus leads to MCC involves a
‘‘perfect storm’’ of events that is
typically catalyzed by UV radiation
exposure, and it includes integration
of viral DNA, expression of small
T-antigen (sT-Ag), truncation/expression
of large T-antigen (tLT-Ag), and evasion
of a destructive immune response.
When the above criteria are met and
MCC develops, it is several times more
likely to be fatal compared with any of
the other more common skin cancers,
including melanoma.
Although MCPyV is ubiquitous and
detection of its DNA by PCR can thus be
difficult to interpret, immunohistochem-
istry data demonstrate persistent expres-
sion of MCPyV oncoproteins in MCC
tumors, and the nature of viral DNA
integration indicates that this virus is not
merely a bystander. Consistent with the
observation that sT-Ag and tLT-Ag are
expressed persistently in human MCC
tumor material, they appear to have
separate and specific roles that are
necessary for the ongoing growth of
MCCs in vitro. Specifically, knocking
down the sT-Ag and tLT-Ag onc-
oproteins results in growth arrest of
MCPyV-driven MCC cells, indi-
cating that ongoing expression of these
oncoproteins is required (Houben et al.,
2010). However, there has been a
debate in the field. For instance, the
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importance of sT-Ag in MCPyV-
mediated transformation has been
controversial, as one research group
reported that knockdown of sT-Ag
leads to growth arrest of MCC cells
(Shuda et al., 2014; Shuda et al.,
2011), whereas another group found
that sT-Ag is dispensable for growth
(Angermeyer et al., 2013). In addition,
MCPyV sT-Ag has the ability to trans-
form cells independent of LT-Ag, which
is not the case for the SV40 polyo-
mavirus (Shuda et al., 2011).
In vitro experiments to understand the
molecular mechanisms of carcinogenesis
have elucidated several transforming
pathways (shared among polyoma-
viruses), but it remains unclear why
MCPyV is the only polyomavirus known
to cause cancer in humans. A fascinat-
ing and critical finding is that the LT-Ag
is invariably truncated in MCC but that
the precise location and nature of the
truncation vary from tumor to tumor
(Shuda et al., 2008). Importantly, how-
ever, the truncation event in LT-Ag is
always downstream of the Rb domain
(Figure 2; this retains Rb inactivating
activity and promotes cell cycle progres-
sion) and upstream of the helicase
domain (which renders the viral origin
irrelevant, thus eliminating virion pro-
duction, which would otherwise be fatal
for the cell (Shuda et al., 2008)).
Perturbing regulatory proteins and
circumventing cell cycle progression
checkpoints are necessary to drive
tumorigenesis, and these are commonly
mediated by viral or cellular oncopro-
teins. A striking example in MCC is Rb
inactivation, which is clearly essential
for MCC development (Sihto et al.,
2011), and this is achieved through
different mechanisms in MCCs that
are MCPyV-positive (via T-antigen
binding) compared with those that are
MCPyV-negative (via mutation of Rb).
A simplified version of the relevant
cell transformation pathways that are
affected by MCPyV oncoproteins is
shown in Figure 2.
MCPyV has two regions that are not
present in other polyomaviruses––
MCPyV Unique Region 1 and 2
(MUR1 & MUR2). MUR2 is not
expressed in MCC because of truncation
of the LT-Ag, but MUR1 is retained in
truncated LT-Ag and thus could mediate
CK20
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Figure 1. Clinical and microscopic images of Merkel cell carcinoma. (a) Representative MCC on the left
hand of a 70-year-old man. Microscopic images with magnified insets of a primary MCC tumor with (b)
hematoxylin and eosin stain showing salt and pepper chromatin pattern, frequent mitotic figures, and
nuclear molding characteristic of MCC; (c) MCPyV Large T-Ag immunohistochemistry (CM2B4 antibody)
shows viral protein expression in tumor cells but not adjacent stroma; (d) Cytokeratin 20 (CK20)
























































Figure 2. MCPyV T-antigen oncoprotein functional interactions with cellular pathways. The MCPyV
small T-antigen (sT-Ag) and truncated large T-antigen (tLT-Ag) are depicted together with their major
known cellular targets. The DnaJ region is present in sT-Ag and LT-Ag amino terminal regions and interacts
with heat-shock protein 70 (Hsp70). Hsp70 binding by sT-Ag and LT-Ag indirectly inactivates the tumor
suppressor protein Rb (Houben et al., 2014), thereby promoting progression from G1 to S phase. The
MUR1 domain of truncated LT-Ag binds and inactivates hVam6p. This inactivation leads to the disruption
of lysosome trafficking, allowing accumulation of certain proteins in the host cell (Liu et al., 2011), possibly
contributing to oncogenesis. The MUR1 domain may have other functions not yet characterized that could
help explain why MCPyV is carcinogenic in humans. Truncated LT-Ag also binds and inactivates Rb
through the LxCxE motif, preventing it from regulating the cell cycle (Houben et al., 2014) and promoting
progression from G1 to S phase. sT-Ag prevents the turnover of hyperphosphorylated 4E-BP1, releasing
activated eIF4E and increasing cap-dependent translation, which contributes to cell transformation (Shuda
et al., 2011). The sT-Ag LSD domain binds Fbxw7, inhibits its ubiquitin ligase activity, and thus promotes
the stability of critical oncogenic proteins including LT-Ag, c-Myc, and cyclin-E (Kwun et al., 2013).
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some of the unique biological properties
of this virus. MUR1 contains a domain
capable of binding hVam6p, a protein
involved in lysosomal trafficking. When
hVam6p is sequestered in HIV-1-infected
cells, lysosomal protein degradation is
reduced and viral progeny production is
increased (Molle et al., 2009). Although
inhibition of hVam6p can thus be
important in the lifecycle of a virus, it is
uncertain whether this protein has a role
in MCC (Houben et al., 2014).
To date, there have been no reports of
transgenic mouse models in which
MCPyV oncoproteins drive carcinogen-
esis successfully. In contrast, many other
polyomaviruses readily cause cancer
in rodents, helping to explain why this
family of viruses was named ‘‘poly-
oma’’ (many tumors).
At last, an MCPyV oncoprotein mouse
model
For decades, the polyomavirus T-Ags
(specifically those from SV40) have
been powerful tools in deciphering the
molecular mechanisms of tumorigenesis
and mammalian cell biology. Indeed,
the use of SV40 T-Ag to transform cells
led to fundamental discoveries such
as the roles of the Rb and p53 tumor
suppressors (Pipas, 2009). However, the
inability to generate a MCPyV-driven
animal model is surprising and has
hindered progress in the field.
Verhaegen et al., have now charac-
terized transgenic mice that constitu-
tively express wild-type sT-Ag under
the control of an epidermis-specific
promoter (keratin-5). These mice
expressed sT-Ag within the stratified
squamous epithelia and developed strik-
ing epithelial dysplasia. The authors
used amino-acid substitution to disrupt
several sT-Ag domains to probe their
relative contributions. When the ‘‘LSD’’
(Large T-antigen Stabilization Domain)
of sT-Ag was mutagenized, transgenic
mice no longer developed epithelial
dysplasia. The authors showed that this
phenotype was likely due to dysregula-
tion of protein degradation. Specifically,
the LSD binds Fbxw7, an E3 ubiquitin
ligase that forms a complex responsible
for tagging proteins destined for
the proteasome. Upon binding Fbxw7,
sT-Ag inactivates this ubiquitin ligase
by sequestering it in the cell nucleus,
leading to the accumulation of
oncogenic proteins such as cyclin-E,
c-Jun, mTOR, and truncated LT-Ag
(Verhaegen et al., 2015). These in vivo
findings agree with earlier studies that
demonstrated LSD function promotes
cellular transformation and supports
survival of MCC cell lines (Kwun et al.,
2013).
Verhaegen et al., note that they
‘‘analyzed pre-term transgenic embryos
to circumvent a potentially severe
phenotype incompatible with postnatal
survival’’, indicating that constitutive
expression of the sT-Ag was lethal. The
toxicity of this transgene underscores the
difficulty of studying MCPyV sT-Ag-
driven transformation. Accordingly, the
authors characterized the inducible
expression of sT-Ag in adult mice, and
they found that this leads to a phenotype
that strongly resembles squamous cell
carcinoma (SCC) in situ. Indeed, ‘‘colli-
sion tumors’’ between MCC and
squamous cell carcinoma (SCC) in situ
(Bowen’s Disease) have been reported
several times in the literature, suggesting
that they may arise from a common
neoplastic precursor lesion. Histological
examination of such collision tumors
often reveals pleomorphic keratinocytes,
characteristic of SCC in situ, admixed
with cells with an MCC phenotype
(hyperchromatic nuclei and peri-nuclear
CK20 staining) (Sirikanjanapong et al.,
2010). These lesions frequently occur
on sun-exposed skin, implicating UV
damage as the underlying etiology of
disease, and, interestingly, are almost
invariably negative for MCPyV. The fact
that the inducible MCPyV sT-Ag mouse
model of Verhaegen et al. develops
SCC-like lesions also suggests that there
are shared pathways between virus-and
UV-driven carcinogenesis in MCC.
Although this inducible mouse model
does not fully recapitulate MCC, it
demonstrates that the LSD domain is
necessary for sT-Ag-driven transforma-
tion of cells in vivo and provides a
valuable tool to the field for exploring
biology and possible therapeutic
approaches.
How might recent pathogenic insights
help patients?
Small molecule inhibitors that selec-
tively target viral proteins or their
cellular targets could provide opportu-
nities to disrupt virus-driven carcinogen-
esis and to ‘‘translate’’ these
mechanistic findings directly toward
clinical benefit. The Chang-Moore
group identified a potent inhibitor of
MCC, YM155 (Arora et al., 2012).
YM155 inhibits translation of survivin,
an oncoprotein that is upre-
gulated in MCC regardless of MCPyV
status, in addition to many other
cancers. In a xenograft mouse model,
YM155 strikingly slowed down the
growth of MCC tumors and induced
non-apoptotic cell death in MCC cell
lines. Accordingly, YM155 has been
tested in several phase I/II clinical trials
for treatment of various cancers, but a
clinical trial of YM155 in MCC has not
yet come to fruition. The inducible sT-
Ag mouse model developed by
Verhaegen et al., could be a useful
model to perform small-molecule
discovery and toxicity studies to
expand opportunities for therapeutic
targets in MCC.
We still do not know
why MCPyV, among all
12 human polyoma-
viruses, is the only one
that causes cancer.
A characteristic of virus-driven can-
cers is the expression of non-self, viral
proteins that should be readily detect-
able by the immune system. Numerous
lines of evidence demonstrate that
immune function is important for recog-
nizing and eliminating MCC. Specifi-
cally, solid organ transplant recipients,
HIV/AIDS patients, and those with
hematologic malignancies are at higher
risk for developing MCC, and they have
poorer outcomes. However, although
over 90% of MCC patients have no
known immune dysfunction, they fail
to eliminate these tumors that persis-
tently express MCPyV oncoproteins.
How do these highly antigenic tumors
evade immunological destruction?
Indeed, several immune evasion mech-
anisms appear to be active in MCC
and in some cases are reversible. Spe-
cifically, over 80% of MCC tumors
downregulate the expression of MHC
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class I (Paulson et al., 2014), thereby
suppressing immune recognition of
MCPyV-derived peptides by CD8 T
cells. In addition, vascular E-selectin
expression is reduced in many MCC
tumors, effectively diminishing the
ability of lymphocytes to migrate into
the tumor microenvironment (Afanasiev
et al., 2013a). When the cellular
immune response is not successfully
subverted by MCC (as assessed by
CD8þ lymphocytes found within the
tumor), 100% disease-specific survival
ensues, even in patients presenting with
advanced nodal or distant metastatic
disease (Paulson et al., 2011).
According to Clinicaltrials.gov, there
are currently 17 active clinical trials that
are specifically designed to include
MCC patients. Seven of these trials
involve immunotherapies that aim to
augment anti-tumor immune responses.
Indeed, MCPyV-specific T cells have
been shown to express elevated levels
of multiple markers of exhaustion such
as PD-1 and TIM-3 (Afanasiev et al.,
2013b). Trials are active that target the
CD8 T-cell response to reverse T-cell
exhaustion via antibodies to PD-1 or
PD-L1. The focus on immune-based
trials in MCC reflects the striking
advances in the field of cancer immuno-
logy, which may be especially relevant
for a virus-driven malignancy.
In summary, the past few years have
provided remarkable insights into how
MCPyV drives this cancer and how the
immune system should typically control
it. These diverse insights promise to
provide us with a more comprehensive
toolbox with which to treat MCC
patients who currently have limited
therapeutic options.
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